Resveratrol-Mediated Reversal of Doxorubicin-Induced Osteoclast Differentiation

Secondary osteoporosis has been associated with cancer patients undertaking Doxorubicin (DOX) chemotherapy. However, the molecular mechanisms behind DOX-induced bone loss have not been elucidated. Molecules that can protect against the adverse effects of DOX are still a challenge in chemotherapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Poudel, Sunil, Martins, Gil, Cancela, M. Leonor, Gavaia, Paulo J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738652/
https://www.ncbi.nlm.nih.gov/pubmed/36499492
http://dx.doi.org/10.3390/ijms232315160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738652/
https://www.ncbi.nlm.nih.gov/pubmed/36499492
http://dx.doi.org/10.3390/ijms232315160

Ejemplares similares